CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine CagriSema vs Semaglutide in Type 2 Diabetes Paramesh Shamanna posted on the topic LinkedIn Novo Nordisk Submits CagriSema for FDA Approval for Obesity Treatment Dr. Jibran Khan R. Ph., CRCP., PhD posted on the topic LinkedIn PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination